Citation Report

List of articles citing

Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels

DOI: 10.1172/JCI83185
Journal of Clinical Investigation, 2016, 126, 4319-4330.

#	Paper	IF	Citations
52	Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes. *Human Molecular Genetics*, **2017**, 26, 3362-3374	5.6	27
51	CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. *Nucleic Acids Research*, **2017**, 45, 5153-5169	20.1	15
50	Therapies targeting DNA and RNA in Huntington's disease. *Lancet Neurology, The*, **2017**, 16, 837-847	24.1	175
49	Trojan triplets: RNA-based pathomechanisms for muscle dysfunction in Huntington's disease. *Journal of General Physiology*, **2017**, 149, 49-53	3.4	
48	Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases. *Brain Sciences*, **2017**, 7,	3.4	33
47	Reduction of Huntington's Disease RNA Foci by CAG Repeat-Targeting Reagents. *Frontiers in Cellular Neuroscience*, **2017**, 11, 82	6.1	9
46	The Generation of Mouse and Human Huntington Disease iPS Cells Suitable for Studies on Huntingtin Function. *Frontiers in Molecular Neuroscience*, **2017**, 10, 253	6.1	13
45	Gene suppression approaches to neurodegeneration. *Alzheimer's Research and Therapy*, **2017**, 9, 82	9	30
44	The central role of DNA damage and repair in CAG repeat diseases. *DMM Disease Models and Mechanisms*, **2018**, 11,	4.1	51
43	Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells. *EMBO Reports*, **2018**, 19,	6.5	20
42	Trinucleotide Repeat Expansion Diseases, RNAi, and Cancer. *Trends in Cancer*, **2018**, 4, 684-700	12.5	11
41	Pharmacogenetic modulation of STEP improves motor and cognitive function in a mouse model of Huntington's disease. *Neurobiology of Disease*, **2018**, 120, 88-97	7.5	8
40	Murine Models of Huntington's Disease for Evaluating Therapeutics. *Methods in Molecular Biology*, **2018**, 1780, 179-207	1.4	6
39	Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-B signaling pathway. *Brain Research*, **2018**, 1697, 21-33	3.7	4
38	Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide. *Molecular Therapy - Nucleic Acids*, **2019**, 17, 601-614	10.7	20
37	One decade ago, one decade ahead in huntington's disease. *Movement Disorders*, **2019**, 34, 1434-1439	7	6
36	Epigenetic dysregulation in the fragile X-related disorders. **2019**, 261-283		

35	The effects of huntingtin-lowering: what do we know so far?. *Degenerative Neurological and Neuromuscular Disease*, **2019**, 9, 3-17	5.4	18
34	Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease. *Neuron*, **2019**, 101, 801-819	13.9	102
33	Repeat-associated non-AUG (RAN) translation: insights from pathology. *Laboratory Investigation*, **2019**, 99, 929-942	5.9	23
32	Genetic cooperativity in multi-layer networks implicates cell survival and senescence in the striatum of Huntington's disease mice synchronous to symptoms. *Bioinformatics*, **2020**, 36, 186-196	7.2	5
31	Interferon mediated neuroinflammation in polyglutamine disease is not caused by RNA toxicity. *Cell Death and Disease*, **2020**, 11, 3	9.8	0
30	Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders. *Brain*, **2020**, 143, 407-429	11.2	28
29	Could metformin be therapeutically useful in Huntington's disease?. *Reviews in the Neurosciences*, **2020**, 31, 297-317	4.7	3
28	Therapeutic antisense oligonucleotides for movement disorders. *Medicinal Research Reviews*, **2021**, 41, 2656-2688	14.4	4
27	A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1. *Frontiers in Genetics*, **2020**, 11, 594576	4.5	5
26	Recent Advances in the Treatment of Huntington's Disease: Targeting DNA and RNA. *CNS Drugs*, **2020**, 34, 219-228	6.7	17
25	Effects of Particulate Matter 10 Inhalation on Lung Tissue RNA expression in a Murine Model. *Tuberculosis and Respiratory Diseases*, **2021**, 84, 55-66	3.2	4
24	Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice. *Acta Neuropathologica*, **2021**, 141, 565-584	14.3	5
23	Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases. *Frontiers in Neuroscience*, **2021**, 15, 621996	5.1	10
22	Lack of Annexin A6 Exacerbates Liver Dysfunction and Reduces Lifespan of Niemann-Pick Type C Protein-Deficient Mice. *American Journal of Pathology*, **2021**, 191, 475-486	5.8	2
21	RNA interference mediates RNA toxicity with parent-of-origin effects in C. elegans expressing CTG repeats.		0
20	Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS. *Molecular Therapy - Nucleic Acids*, **2021**, 24, 1-10	10.7	3
19	Molecular mechanisms underlying nucleotide repeat expansion disorders. *Nature Reviews Molecular Cell Biology*, **2021**, 22, 589-607	48.7	23
18	DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases. *Neurotherapeutics*, **2021**, 18, 1710-1728	6.4	1

17	Oligonucleotides Targeting DNA Repeats Downregulate Gene Expression in Huntingtonʼs Patient-Derived Neural Model System. *Nucleic Acid Therapeutics*, **2021**,	4.8	2
16	Gene targeting techniques for Huntingtonʼs disease. *Ageing Research Reviews*, **2021**, 70, 101385	12	1
15	Some Molecular and Cellular Stress Mechanisms Associated with Neurodegenerative Diseases and Atherosclerosis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
14	Conformational flexibility in the RNA stem-loop structures formed by CAG repeats. *FEBS Letters*, **2017**, 591, 1752-1760	3.8	1
13	Antiviral effects of hepatitis B virus S gene-specific anti-gene locked nucleic acid in transgenic mice. *World Journal of Clinical Cases*, **2018**, 6, 183-191	1.6	1
12	The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. *PLoS ONE*, **2017**, 12, e0171127	3.7	37
11	Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. *Current Neuropharmacology*, **2019**, 17, 563-579	7.6	22
10	Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells.		
9	Innovative Therapeutic Approaches for Huntingtonʼs Disease: From Nucleic Acids to GPCR-Targeting Small Molecules.. *Frontiers in Cellular Neuroscience*, **2021**, 15, 785703	6.1	5
8	A review on Huntington protein Insight into protein aggregation and therapeutic interventions.. *Current Drug Metabolism*, **2022**,	3.5	1
7	RTP801/REDD1 Is Involved in Neuroinflammation and Modulates Cognitive Dysfunction in Huntingtonʼs Disease.. *Biomolecules*, **2021**, 12,	5.9	1
6	Asymmetric inheritance of RNA toxicity in expressing CTG repeats.. *IScience*, **2022**, 25, 104246	6.1	1
5	Standardizing the CAP Score in Huntingtonʼs Disease by Predicting Age-at-Onset.. *Journal of Huntingtonʼs Disease*, **2022**,	1.9	2
4	Data_Sheet_1.docx. **2020**,		
3	A peptide inhibitor that rescues polyglutamine-induced synaptic defects and cell death through suppressing RNA and protein toxicities. *Molecular Therapy - Nucleic Acids*, **2022**, 29, 102-115	10.7	
2	The length of uninterrupted CAG repeats in stem regions of repeat disease associated hairpins determines the amount of short CAG oligonucleotides that are toxic to cells through RNA interference. **2022**, 13,		0
1	Divergent cognitive trajectories in early stage Huntingtonʼs disease: A 3-year longitudinal study.		0